At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Trading 12-23 14:15:51
81.100
-0.700
-0.86%
High83.250Low80.900Vol5.16M
Open81.800D1 Closing81.800Amplitude2.87%
Mkt Cap139.57BTradable Cap139.57BTotal Shares1.72B
T/O423.46MT/O Rate0.30%Tradable Shares1.72B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Southbound Capital Flow Statistics (T+2) for Dec 23
Stock News  ·  07:39
Southbound Capital Flow Statistics (T+2) for Dec 23
Hong Kong Market Insights: Hainan Free Trade Port Closure Holds Major Significance; Autonomous Driving Sector Sees Intensive Catalysts
Stock News  ·  12-19
Hong Kong Market Insights: Hainan Free Trade Port Closure Holds Major Significance; Autonomous Driving Sector Sees Intensive Catalysts
Innovent Biologics (SEHK:1801): Reassessing Valuation After Landmark Nature Phase 3 Mazdutide Publications
Simply Wall St.  ·  12-19
Innovent Biologics (SEHK:1801): Reassessing Valuation After Landmark Nature Phase 3 Mazdutide Publications
Zhitong HK Morning Briefing | State Council Issues Guidelines on Combating Tobacco-Related Illegal Activities; Overnight US Stocks Rise Across the Board
Stock News  ·  12-19
Zhitong HK Morning Briefing | State Council Issues Guidelines on Combating Tobacco-Related Illegal Activities; Overnight US Stocks Rise Across the Board
Innovent Biologics Publishes Landmark Phase 3 Mazdutide Diabetes Trials in Nature
Reuters  ·  12-18
Innovent Biologics Publishes Landmark Phase 3 Mazdutide Diabetes Trials in Nature
Why Innovent Biologics (SEHK:1801) Is Down 7.4% After Promising Adolescent Obesity Data For Mazdutide
Simply Wall St.  ·  12-15
Why Innovent Biologics (SEHK:1801) Is Down 7.4% After Promising Adolescent Obesity Data For Mazdutide
Hong Kong Stock Short Interest Data as of December 12
Stock News  ·  12-12
Hong Kong Stock Short Interest Data as of December 12
Innovent Biologics Reports Mazdutide Achieves Significant Weight Loss in Chinese Adolescents with Obesity
Reuters  ·  12-12
Innovent Biologics Reports Mazdutide Achieves Significant Weight Loss in Chinese Adolescents with Obesity
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1B Clinical Trial in Chinese Adolescents With Obesity
THOMSON REUTERS  ·  12-12
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1B Clinical Trial in Chinese Adolescents With Obesity
Innovent Biologics (SEHK:1801): Reconciling a 116x P/E With DCF-Suggested Upside
Simply Wall St.  ·  12-10
Innovent Biologics (SEHK:1801): Reconciling a 116x P/E With DCF-Suggested Upside
BOCOM INTL: Medical Insurance and Commercial Insurance Catalogs Implemented, Diversified Payment Systems to Drive Incremental Space for Innovative Drugs
Stock News  ·  12-10
BOCOM INTL: Medical Insurance and Commercial Insurance Catalogs Implemented, Diversified Payment Systems to Drive Incremental Space for Innovative Drugs
Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares
Reuters  ·  12-10
Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of Ibi3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
THOMSON REUTERS  ·  12-10
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of Ibi3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2
Stock News  ·  12-09
CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2
Innovent Biologics' PECONDLE Achieves Phase 3 Success for Moderate-to-Severe Psoriasis
Reuters  ·  12-09
Innovent Biologics' PECONDLE Achieves Phase 3 Success for Moderate-to-Severe Psoriasis
Innovent Announces Pecondle® (Picankibart Injection) Phase 3 Study (Clear-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
THOMSON REUTERS  ·  12-09
Innovent Announces Pecondle® (Picankibart Injection) Phase 3 Study (Clear-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
HK Stock Movement | INNOVENT BIO (01801) Plunges Over 6% with Block Trades Worth Over HK$1.2 Billion Pre-Market
Stock News  ·  12-08
HK Stock Movement | INNOVENT BIO (01801) Plunges Over 6% with Block Trades Worth Over HK$1.2 Billion Pre-Market
Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma
Reuters  ·  12-08
Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma
Ash 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody Ibi3003 in Relapsed or Refractory Multiple Myeloma
THOMSON REUTERS  ·  12-08
Ash 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody Ibi3003 in Relapsed or Refractory Multiple Myeloma
Hong Kong Stock Short Selling Stats | Dec 8
Stock News  ·  12-08
Hong Kong Stock Short Selling Stats | Dec 8

Introduction

Company Name.
INNOVENT BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
Issue price:
--